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Background: The use of laparoscopic gastrectomy (LG) in advanced gastric cancer (AGC) remains a controversial
topic, mainly because of doubts about its oncologic validity. This study is a systematic review and meta-analysis of
the available evidence.
Methods: A comprehensive search was performed until June 2013 to identify comparative studies evaluating
survival rates, recurrence rates, surgical outcomes and complications. Pooled risk ratios (RR) and weighted mean
differences (WMD) with 95% confidence intervals (CI) were calculated using the random effects model. Data
synthesis and statistical analysis were carried out using RevMan 5.1 software.
Results: Fifteen trials were involved in this analysis. Compared to open gastrectomy (OG), LG involved a longer
operating time (WMD = 48.67 min, 95% CI 34.09 to 63.26, P < 0.001); less blood loss (WMD = −139.01 ml, 95%
CI −174.57 to −103.44, P < 0.001); earlier time to flatus (WMD = −0.79 days, 95% CI −1.14 to −0.44, P < 0.001);
shorter hospital stay (WMD = −3.11 days, 95% CI −4.13 to −2.09, P < 0.001); and a decrease in complications
(RR = 0.74, 95% CI 0.61 to 0.90, P = 0.003). There was no significant difference in the number of harvested lymph
nodes, margin distance, mortality, cancer recurrence rate and long-term survival rate between the AGC patients
treated with LG or OG (P > 0.05).
Conclusions: Despite a longer operation, LG is a safe technical alternative to OG for AGC with a lower complication
rate and enhanced postoperative recovery. Moreover, there were similar outcomes between both approaches in
terms of cancer recurrence and the long-term survival rate. Because of the limitation of this study, methodologically
high-quality studies are needed for further evaluation.Background
Although the annual incidence of and mortality from
gastric cancer have been decreasing yearly worldwide,
gastric cancer still accounts for more than 10% of cancer
deaths worldwide and is the second most frequent cause
of cancer death after lung cancer [1,2]. Adjuvant chemo-
therapy improves the survival of these patients [3,4], but
radical gastrectomy with regional lymph node dissection
still remains the only potentially curative treatment
available for gastric adenocarcinoma [5,6].
Since the first report of laparoscopic gastrectomy (LG)
for early gastric cancer (EGC) by Kitano [7], it has* Correspondence: mouyiping2002@163.com
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reproduction in any medium, provided the orundergone rapid development and gained popularity in
the past 20 years. Compared to traditional open gastrec-
tomy (OG), most studies have reported that LG can achieve
better cosmesis, shorter hospital stay, faster recovery and
better postoperative quality of life [8-13]. However, most of
these studies focus on EGC. LG for advanced gastric cancer
(AGC) remains controversial and has not achieved univer-
sal acceptance because of its uncertain oncological safety,
particularly given the technical difficulty of lymphadenec-
tomy for metastatic lymph nodes [14]. Meanwhile, there
have been few long-term follow-up results regarding the
oncological adequacy of laparoscopic surgery compared to
that of open surgery for AGC.
Although several meta-analyses and systematic reviews
have demonstrated the safety and oncological effect
of LG for EGC [15-19], such studies have not beentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of LG for AGC. The aim of this study was to compare
LG with OG with respect to morbidity, mortality, in-
traoperative outcomes and functional recovery. Long-
term outcomes after LG and OG in patients with AGC
were evaluated in a systematic review of the literature,
and meta-analyses were performed.
Methods
Literature search
A systematic search using the following keywords,
“laparoscopy”, “laparoscopic”, “gastric cancer”, “gastric
carcinoma” and “gastrectomy”, was performed through
the following bibliographic databases, PubMed, Web of
Science and Cochrane Library, for literature comparing
LG and OG published between January 1995 and June
2013, and we broadened the search range by browsing
the related summary, methods and references of re-
trieved articles. The language of the publications was
confined to English. Two investigators reviewed the ti-
tles and abstracts, and assessed the full text to establish
eligibility.
Study selection criteria
All clinical studies needed to meet the following criteria
for the meta-analysis: (1) being published in English with
data comparing LG and OG for AGC; (2) having clear
case selection criteria and surgical methods; they had to
contain long-term outcomes such as tumor recurrence
and survival rate; (3) articles referring only or predomin-
antly to AGC, because it is difficult to confirm AGC
preoperatively [20]. However, articles with significant
differences in tumor stages between groups were ex-
cluded. (4) If there was an overlap between authors or
centers, only the higher quality or more recent literature
was selected. However, articles from the same authors or
centers but with different patient cohorts were included.
Data extraction and quality assessment
Two authors independently extracted the data using a
unified data sheet and decided upon the controversial
issues through discussion. Extracted data included the
author, study period, geographical region, number of pa-
tients, operating time, blood loss, number of retrieved
lymph nodes, proximal and distal margin distance, time
to flatus, time to oral intake, length of hospital stay,
morbidity and mortality, tumor recurrence and survival
rate. Postoperative complications were classified as me-
dical (cardiovascular, respiratory or metabolic events;
nonsurgical infections; deep venous thrombosis; pulmon-
ary embolism) or surgical (any anastomotic leakage or
fistula, any complication that required reoperation, intra-
abdominal collections, wound complications, bleeding
events, pancreatitis, ileus, delayed gastric emptying andanastomotic stricture). This classification system is based
on the Memorial Sloan-Kettering Cancer Center com-
plication reporting system [21]. If necessary, the first au-
thors were contacted to retrieve further information.
Randomized controlled trials (RCTs) were evaluated
by the Jadad composite scale. High-quality trials scored
more than 2 out of a maximum possible score of 5. The
Newcastle-Ottawa Quality Assessment Scale (NOS) was
used for quality assessment of observational studies. A
threshold of six stars or above has been considered indi-
cative of high quality.
Statistical analysis
The meta-analysis was performed in line with re-
commendations from the Cochrane Collaboration and the
Quality of Reporting of Meta-Analyses guidelines [22,23].
Continuous variables were assessed using the weighted
mean difference (WMD), and dichotomous variables were
analyzed using the risk ratio (RR). If the study provided
medians and ranges instead of means and standard devia-
tions (SDs), we estimated the means and SDs as described
by Hozo et al. [24]. To account for clinical heterogeneity,
which refers to diversity in a sense that is relevant for clin-
ical situations, we used the random effects model based
on DerSimonian and Laird’s method. Potential publication
bias was determined by conducting informal visual
inspection of funnel plots based on the complications.
Data analyses were performed using Review Manage ver-
sion 5.1 (RevMan 5.1) software downloaded from the




The initial search strategy retrieved 2,068 publications in
English. After the titles and abstracts had been reviewed,
papers without comparison of LG and OG for AGC
were excluded, which left 21 comparative studies, 6
[25-30] of which did not meet the inclusion criteria and
were excluded. This left a total of two RCTs and 13 ob-
servational studies [31-45], all of which were accessible
in full-text format. A flow chart of the search strategies
is illustrated in Figure 1.
Study characteristics and quality
A total of 2,519 patients were included in the analysis
with 1,327 undergoing LG (52.7%) and 1,192 undergoing
OG (47.3%). They represent international experience in-
cluding data from five different countries (six from
China, four from Korea, three from Italy, one from Japan
and one from Chile). Two RCTs got Jadad scores of 2
and 3, respectively. According to the NOS, 2 out of the
13 observational studies got 7 stars, 6 articles got 8 stars,
and the remaining 5 got 9 stars. The characteristics and
Initial literature seach (n=2068)
Articles retrieved for full-text 
evalution (n=21)
Abstracts excluded because of not comparing LG
and OG for AGC (n=2047)
Articles excluded because of failure to meet 
inclusion criteria (n=7)[25-30]
Reasons: Overlap between authors or 
centers(n=2)[25,26]; tumor stages were significantly
different (n=2)[27,28]; without long-term survival
outcomes(n=1)[29]; surgical method and level of
lymphadenectomy not clare(n=1)[30]
Articles suitable for meta-analysis 
(n=15) [31-45]
Figure 1 Flow chart of literature search strategies.
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studies are shown in Table 1.
Intraoperative effects
The mean operating time of LG was 48.67 min longer
than for OG (WMD = 48.67 min, 95% CI 34.09 to 63.26,
P < 0.001). The intraoperative blood loss was lower in
LG than in OG (WMD = −139.01 ml, 95% CI −174.57
to −103.44, P < 0.001). All studies contained the number
of retrieved lymph nodes. The difference in the mean
number of retrieved lymph nodes between LG and OG
was not significant in the pooled data (WMD = −0.07,
95% CI −1.03 to 0.89, P = 0.88) (Figure 2). Meta-analysis
of the distal margin distance showed no significant dif-
ference between the two groups (WMD = 0.08 cm, 95%
CI −0.16 to 0.32, P = 0.50). However, the proximal mar-
gin distance of OG was longer than that of LG with a
marginal difference (WMD = −0.26 cm, 95% CI −0.54 to
0.01, P = 0.06). All intraoperative effect outcomes are
summarized in Table 2.
Postoperative outcome
The mean time to first flatus was shorter in LG than in
OG (WMD = −0.79 d, 95% CI −1.14 to −0.44, P <
0.001), as was the time to restart oral intake after surgery
(WMD = −1.06 d, 95% CI −1.63 to −0.50, P < 0.001). A
shorter hospital stay was also observed in the LG group
(WMD = −3.11 d, 95% CI −4.13 to −2.09, P < 0.001).
Mortality was described in seven studies, and there was
no significant difference in postoperative mortality (RR =
0.78, 95% CI 0.30 to 2.04, P = 0.61). The rate of overall
postoperative complications was lower for LG (RR = 0.74,
95% CI 0.61 to 0.90, P = 0.003) (Figure 3). Visual inspec-
tion of the funnel plot revealed symmetry, indicating no
serious publication bias (Figure 4). After further analysis,
surgical complications were also lower for LG (RR = 0.73,
95% CI 0.58 to 0.92, P = 0.007). In analyzing the specific
complications, wound infection and ileus were lower forLG (wound infection: RR = 0.53, 95% CI 0.33 to 0.85, P =
0.009; ileus: RR = 0.27, 95% CI 0.09 to 0.75, P = 0.01).
Other surgical complications such as anastomotic leakage,
intra-abdominal collections, bleeding or anastomotic stric-
ture were similar between groups (P > 0.05). Besides,
LG was associated with a marginal reduction in medical
complications (RR = 0.65, 95% CI 0.41 to 1.02, P = 0.06)
with a possible contribution from respiratory complica-
tions (RR = 0.57, 95% CI 0.30 to 1.10, P = 0.09). All post-
operative outcomes are summarized in Table 2.
Recurrence and long-term survival rate
Ten studies reported the cancer recurrence [31-35,39,
41-43,45]. The recurrence risk in LG was 29.9% (288/
964) and 30.5% (288/943) in OG, but the difference be-
tween LG and OG was not significant (RR = 0.94, 95%
CI 0.83 to 1.08, P = 0.38) (Figure 5). The available data
about recurrence patterns and specific recurrent sites
are summarized in Table 3.
Another four studies [31,43-45] available reported no
port-site metastases in the LG group. Hwang et al. [34]
reported a port-site recurrence 10 months after LG.
Zhao et al. [39] reported a case of port-site recurrence
13 months after LG group; a case of incision metastasis
and a case of metastasis in the orifice of the abdominal
drain tube 27 and 9 months, respectively, after OG
group. Moison et al. [43] reported tumors recurred in
distant sites in three patients in the LG and in two pa-
tients in the OG group, and a recurrence in the remnant
stomach in the LG group. Shinohara et al. [45] reported
53 recurrences in the LG group: 29 (54.7%) from periton-
eal recurrence, 23 (43.4%) from distant or hematogenous
recurrence and 15 (28.3%) from locoregional or lymphatic
recurrence; the corresponding findings in the OG group
were 17 (50%), 15 (44.1%) and 11 (32.6%), respectively.
Twelve studies reported postoperative survival rates
[31-33,36,37,39-45], all of which did not find significant
differences in survival rates between groups. Although
Table 1 Characteristics of included studies








Reconstruction Adjuvant chemotherapy (%) Quality
scoresLG OG LG OG
Huscher Italy RCT 2005 1992-1996 30 29 D1, D2 DG B-II, R-Y NR NR 3*
Hur Korea Retrospective 2008 2004-2007 26 25 D2 DG B-I, B-II 76.9 68 8
Du XH China Retrospective 2009 2004-2008 78 90 D2 DG B-I, B-II NR NR 7
Hwang Korea Retrospective 2009 2004-2007 45 83 D1 + α/β, D2 DG B-I, B-II 93.2 89.0 7
Du J China Retrospective 2010 2005-2009 82 94 D2 TG R-Y 100 100 8
Cai China RCT 2011 2008-2009 49 47 D2 DG, PG, TG B-I, B-II, R-Y 100 100 2*
Scatizzi Italy Retrospective 2011 2006-2009 30 30 D2 DG R-Y NR NR 8
Shuang China Retrospective 2011 2005-2007 35 35 D2 DG B-II NR NR 8
Zhao China Retrospective 2011 2004-2009 346 313 D1 + α/β, D2 DG B-I, B-II 93.1 91.7 9
Chen China Retrospective 2012 2008-2010 224 112 D2 DG, TG B-I, B-II, R-Y NR NR 8
Chun Korea Retrospective 2012 2004-2009 52 67 D2 DG B-I, B-II, R-Y NR NR 9
Kim Korea Retrospective 2012 1999-2007 88 88 D2 DG, TG B-I, B-II, R-Y NR NR 9
Moisan Chile Retrospective 2012 2005-2010 31 31 D1 + α/β, D2 DG, TG B-II, R-Y 19.4 22.6 8
Siani Italy Retrospective 2012 2003-2009 25 25 D1 + α/β, D2 TG R-Y NR NR 9
Shinohara Japan Retrospective 2013 1998-2008 186 123 D2 DG, PG, TG B-I, R-Y 61.3 58.5 9
Abbreviations: RCT Randomized controlled trial, LG Laparoscopic gastrectomy, OG Open gastrectomy, DG Distal gastrectomy, PG Proximal gastrectomy, TG Total gastrectomy, B-I Billroth-I, B-II Billroth-II, R-Y Roux-en-Y,




















Figure 2 Meta-analysis of the pooled data: number of retrieved lymph nodes.
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they also found no significant difference in the survival
rates between the two groups after 50 months of follow-
up (P > 0.05). Meta-analysis of these available data dem-
onstrated that the disease-free survival (DFS) rate was
not significantly different in participants who received
LG compared with OG (3-year: RR = 1.11, 95% CI 0.75
to 1.65, P = 0.59; 5-year: RR = 1.03, 95% CI 0.93 to 1.14,
P = 0.56) (Figure 6), nor was the overall survival (OS)
rate (1-year: RR = 1.01, 95% CI 0.96 to 1.05, P = 0.79; 3-
year: RR = 1.08, 95% CI 0.99 to 1.17, P = 0.07; 5-year:





Operating time (min) 15 1327 1192 <0.
Blood loss (ml) 12 1157 1007 <0.
Retrieved lymph nodes 15 1327 1192 0.
Proximal margin (cm) 6 588 607 0.
Distal margin (cm) 4 517 499 0
Analgesics given (days) 4 192 242 <0.
Time to ambulation (days) 6 913 755 <0.
Time to first flatus (days) 11 1045 974 <0.
Time to oral intake (days) 9 967 793 <0.
Hospital stay (days) 14 1238 1091 <0.
Overall complications 15 1327 1192 0
Surgical complications 15 1,327 1,192 0
Medical complications 12 868 754 0
Mortality 7 965 821 0
Abbreviations: WMD Weighted mean difference, RR Risk ratio.systematic review outcomes of long-term survival rates
are summarized in Table 4.
Discussion
RCTs are the most ideal tool for meta-analysis. However,
it is difficult to conduct a high-quality RCT to evaluate a
new surgical intervention because of obstacles such as
learning curve effects, ethical and cultural resistance, and
urgent or unexpected conditions during the operation. For
these reasons, to include non-RCTs is an appropriate
strategy to extend the source of evidence. Therefore, our







001, 93% WMD = 48.67 34.09−63.06 <0.001
001, 91% WMD = −139.01 −174.57− −103.44 <0.001
26, 17% WMD = −0.07 −1.03−0.89 0.88
27, 21% WMD = −0.26 −0.54−0.01 0.06
.86, 0% WMD = 0.08 −0.16−0.32 0.50
001, 89% WMD = −1.57 −2.40− −0.74 <0.001
001, 96% WMD = −1.01 −1.56− −0.45 <0.001
001, 94% WMD = −0.79 −1.14− −0.44 <0.001
001, 87% WMD = −1.06 −1.63− −0.50 <0.001
001, 84% WMD = −3.11 −4.13− −2.09 <0.001
.66, 0% RR = 0.74 0.61−0.90 0.003
.56, 0% RR = 0.73 0.58−0.92 0.007
.40, 5% RR = 0.65 0.41−1.02 0.06
.75, 0% RR = 0.78 0.30−2.04 0.61
Figure 3 Meta-analysis of the pooled data: overall postoperative complications.
Chen et al. World Journal of Surgical Oncology 2013, 11:182 Page 6 of 12
http://www.wjso.com/content/11/1/182with strictly limiting inclusion and exclusion criteria to
evaluate the safety and efficacy of LG in patients with AGC
to determine whether LG is an acceptable alternative to
OG. The quality scores of the included observational stud-
ies got 7 or more stars according to the NOS. These studies
were primarily derived from the countries with the most
widespread use of LG and mainly published in the past 5
years (2009–2013). Meta-analysis conducted based on this
principle will contribute a more comprehensive and object-
ive evaluation for the current status of LG treating AGC.
Reduction in the intraoperative blood loss is a consist-
ent finding in studies comparing laparoscopic and open
techniques in many different clinical situations. This isFigure 4 Funnel plot of the overall postoperative complications.because laparoscopic surgery is more delicate than open
surgery in providing perfect amplification. Regarding the
operating time, LG is more time-consuming than OG.
LG combined with lymphadenectomy is a complex oper-
ation and needs extensive technical expertise. Studies
designed to estimate the learning curve have shown a
significant reduction in operating time after about 50 LG
cases [46-48]. Research from some large specialized
centers reported that the operating time of LG was not
longer than OG in experienced hands [40,49]. Various
modified techniques could help to simplify the procedure
of reconstruction and shorten the operating time [49,50].
Therefore, researchers expect that with proficiency in
Figure 5 Meta-analysis of the pooled data: recurrences.
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ment of equipment the time required for LG will be-
come shorter [17].
One of the most striking findings was a reduced num-
ber of complications including surgical and medical ones
in the LG versus OG group. Meta-analysis of the speci-
fied complications demonstrated that wound infections
and ileus were significantly less common in the LG
group. The reduced surface area of incisions and the
manual handling of organs limit the risk of surgical site
infections and ileus. It was not surprising that other sur-
gical complications were not reduced because the lap-
aroscopic technique, although less invasive, results in
the same organ and lymphatic resection as the open pro-
cedure. Besides, the decreased medical complications
could be explained by the reduced invasiveness of the
laparoscopic technique and less pain after surgery.
We also found that respiratory complications occurred
in LG less often than in OG, although the difference was
not significant (P = 0.09). The pain caused by a large
incision as well as the use of tension sutures and abdominalTable 3 Systematic review of recurrence patterns and specific
Author Group Sample size
Total LR
Hur LG 26 8 3
OG 25 6
Du J LG 82 19 10
OG 94 23 10
Chun* LG 52 4
OG 67 7 1
Kim* LG 88 13 2
OG 88 15 2
Abbreviations: LR Local recurrence, LN Lymph node; *some patients had mixed tumbandages after laparotomy can make it difficult for patients
to cough, expectorate and perform breathing exercises ef-
fectively, thus leading to such complications as pulmonary
infection [51]. Reduced use of analgesic drugs, shortened
time of abdominal cavity exposure and earlier postoperative
activities are considered to be the main reasons for earlier
gastrointestinal recovery from LG.
The concern about the technical difficulty of lymphad-
enectomy for perigastric lymph nodes is one of the
major obstacles to accepting LG for AGC. Indeed, the
adequacy of the radical resection should be evaluated by
the extent of lymph node dissection performed and the
number of retrieved lymph nodes. Our meta-analysis
-revealed that there was no evident difference in the
number of lymph nodes dissected between two groups,
which was different from the results of some early meta-
analyses [16,17,52]. In recent years, with improved equip-
ment and increased surgeon experience, the number of
lymph nodes dissected by LG has gradually increased
[8,53]. Moreover, some researchers have reported not
only a similar number of overall retrieved lymph nodesrecurrent sites
Tumor recurrence
LN Liver Lung Bone Peritoneum





5 1 1 3
4 6 3 5
4 4 3 2
or recurrence.
Figure 6 Meta-analysis of the pooled data: survival rate. (A) 3y-DFS, (B) 5y-DFS, (C) 1y-OS, (D) 3y-OS and (E) 5y-OS. DFS, disease-free survival;
OS, overall survival; y, year.
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Table 4 Systematic review of long-term survival outcomes
Author Group Follow-up (months) Recurrence DFS rate OS rate
Huscher LG 60 (2–88) 11 5-y: 57.3 5-y: 58.9
OG 55 (7–90) 10 5-y: 54.8 5-y: 55.7
Hur LG 29 (6–47) 8 3-y: 71.4 3-y: 88.2
OG 6 3-y: 53.4 3-y: 77.2
Du XH LG 25.2 (4–58) 22 NR 3-y: 81.2
OG 31 NR 3-y: 74.7
Hwang LG 23 (9–40) 6 NR NR
OG 23.5 (8–41) 17 NR NR
Du J LAG 25 (2–44) 19 NR NR
OG 23 NR NR
Cai LG 22.1 (4–36) NR NR 3-y: 67.1
OG NR NR 3-y: 53.8
Scatizzi LG 18 (2–37) NR NR 3-y: 70.9
OG 18 (7–42) NR NR 3-y: 56.8
Shuang LG 36.5 (23–50) NR NR NR
OG 38.5 (27–50) NR NR NR
Zhao LG 37 (6–72) 147 5-y: 47 1-y: 87.2, 3-y: 57.2, 5-y: 50.3
OG 141 5-y: 46.8 1-y: 87.1, 3-y: 54.1, 5-y: 49.2
Chen LG 19 (1–48) NR NR 1-y: 91.5
OG NR NR 1-y: 89.8
Chun LG 53.2 (1–82.2) 4 NR 5-y: 91.3
OG 60.4 (7–91.7) 7 NR 5-y: 88.6
Kim LG 53.7 (8.3−138.1) 13 5-y: 84.6 5-y: 85.9
OG 58.1 (0.3−106.2) 15 5-y: 81.1 5-y: 83.1
Moisan LG 28 5 3-y: 79.4 3-y: 82.3
OG 40 4 3-y: 83.4 3-y: 86.9
Siani LG 32.6 NR 5-y: 54.2 5-y: 55.7
OG 31.9 NR 5-y: 52.1 5-y: 52.9
Shinohara LG 48.8 (25–58.5)a 53 5-y: 65.8b 5-y: 68.1b
OG 34 5-y: 62.0b 5-y: 63.7b
Abbreviations: DFS Disease-free survival, OS Overall survival, y Year, NR Not reported.
Follow-up time are shown as median (range); ashown as interquartile range; bcalculated by excluding stage IA and missing follow-up patients.
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cific lymph nodes, such as group 7, 8a, 9, 11p, 12a and
14v, which used to be considered difficult for laparo-
scopic dissection [54]. Park et al. [55] evaluated the long-
term outcomes of 239 patients who underwent LG for the
treatment of advanced gastric cancer. They found that the
major recurrence was distant metastasis, whereas relapsed
lymph nodes were most frequent in para-aortic or distant
lymph node metastasis. Therefore, we believe that the dis-
section of lymph nodes around the stomach can be
performed efficiently under laparoscope. Besides, splenic
hilar lymph node dissection is one of the difficulties in
upper and middle gastric cancer because the splenic ves-
sels run circuitously, the branches vary substantially, andthey are in a narrow and deep space. Therefore, it is easy
to cause hemorrhage or spleen ischemia and further ne-
crosis accidentally. Compared to laparotomy, laparoscopy
allows the operator to complete the spleen hilum lymph
node dissection under a clear field of view and helps to
improve safety [56].
Cancer recurrence and the long-term survival rate are
two critical outcomes for evaluating surgical interven-
tions in oncological therapy. Based on the available data,
postoperative cancer recurrence and the long-term sur-
vival rate in LG were similar to those in OG. Regarding
the recurrence pattern, Song et al. [57] stated that the
hematogenous pattern was most common after LG,
followed by the locoregional pattern. This is consistent
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other research [30]. The concern about dissemination of
gastric cancer due to insufflated gas from pneumo-
peritoneum and port site or wound metastasis, although
quite rare, has been emphasized. Port-site recurrence
was seen in two of included studies [34,39]; however, it
was not an event unique to LG, because there were also
two cases of wound metastasis in OG group [39]. Zhao
et al. and others [39,58] stated that laparoscopic surgery
does not promote abdominal or trocar implantation of
gastric cancer. As previously mentioned, researchers in-
dicated that LG did not increase the risk of perigastric
lymph node recurrence compared to OG [55]. Sato
et al. [59] analyzed the difference between OG and LG
in relation to D1, D1+ or D2 lymph node dissection
using a hierarchical approach and found that the long-
term results of LG were comparable to those of OG.
Park et al. [55] analyzed the follow-up results of 239
cases of AGC treated with LG. The 5-year survival rates
of T2, T3 and T4 stage patients were 86.6%, 77.4% and
58.7%, respectively, which is similar to that for concur-
rent laparotomy [60,61].
However, there were several limitations that must be
taken into account when considering the above-men
tioned results: (1) tumor depth and nodal status were
risk factors for recurrence, and survival for patients with
pT2 cancer has been reported to be better than that for
patients with other advanced stage [62,63]. Two of the
included studies were limited to pT2 stage patients [32,41],
and some of others mainly referred to stage IB-II or pT2-3
tumor invasion [34,36,38,40,42,43,45]. Hence, there should
be an attitude of caution concerning laparoscopic resection
of more advanced cases because relevant studies and clin-
ical evidence are still deficient; (2) postoperative adjuvant
chemotherapy has demonstrated a clear survival benefit
compared to treatment with surgery alone [3,4]. However,
some included studies failed to provide such information
[31,33,37,38,40-42,44], which might have affected the re-
sults; (3) the homogeneity test for the continuous variables
exhibited substantial heterogeneity due to the inherent
flaws of a retrospective study, the uneven surgical skills of
the different surgeons as well as regional differences, etc.
Conclusions
The existing research shows that LG for AGC is safe
and feasible, characterized by such advantages as less
pain, fewer postoperative complications and rapid reco-
very. Moreover, our results suggest that the application
of LG to this group results in adequate lymphadenec-
tomy and similar recurrence and survival rates as OG.
However, there were several limitations in this research.
Therefore, the results mentioned above should be sub-
ject to verification by strictly designed, large-sample,
multicenter RCTs with extended follow-up outcomes.Abbreviations
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